Eli Lilly sues 6 sellers of black-market weight-loss drug

Retatrutide is still in clinical trials, but backyard chemists have been making knockoff versions for months. They sell them through wellness clinics and online shops as a cheaper stand-in for Ozempic or Zepbound. Eli Lilly says it's had enough. On Wednesday the company sued six U.S. sellers. It accuses them of making and distributing fake retatrutide. There's no regulatory approval, and no proof of what's in the vials.

Lilly isn't just suing. It's also asking payment companies and online marketplaces to cut these sellers off directly. Courts move slowly, and copycat sellers pop up fast. That's an unusual step for a drugmaker. But it echoes what's already happened with approved GLP-1 drugs. Counterfeit and off-label sales have become a problem regulators haven't fully stopped.

Keep reading — what to watch

Will cutting off payment processors work where lawsuits haven't? Copycat retatrutide sellers can reopen under a new name within days. Demand for cheaper GLP-1 knockoffs isn't going away while the real drugs stay expensive and hard to get. The bigger test comes once retatrutide itself wins approval. Real supply might finally undercut the black market, or sellers might just adapt again.